STRONGBRIDGE BIOPHARMA plc Selling, General and Administrative Expense
STRONGBRIDGE BIOPHARMA plc reported Selling, General and Administrative Expense of $15.99 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2021-08-05
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for the quarter ending 2021-06-30 was $15.99M, a 65.89% increase year-over-year.
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for the quarter ending 2021-03-31 was $10.95M, a 5.22% increase year-over-year.
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for the quarter ending 2020-12-31 was $11.61M, a 3.05% decline year-over-year.
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for the quarter ending 2020-09-30 was $9.22M, a 27.99% decline year-over-year.
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for fiscal 2020 was $40.87M, a 16.70% decline from fiscal 2019.
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for fiscal 2019 was $49.06M, a 22.54% decline from fiscal 2018.
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for fiscal 2018 was $63.34M, a 74.52% increase from fiscal 2017.
- STRONGBRIDGE BIOPHARMA plc selling, general and administrative expense for fiscal 2017 was $36.29M, a 143.98% increase from fiscal 2016.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2021-06-30 | $15.99M 10-Q · filed 2021-08-05 | $26.93M 10-Q · filed 2021-08-05 | $38.54M derived: sum of 3 quarters · filed 2021-08-05 | $47.76M derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | $10.95M 10-Q · filed 2021-05-12 | $22.55M derived: sum of 2 quarters · filed 2021-05-12 | $31.77M derived: sum of 3 quarters · filed 2021-05-12 | $41.41M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-12-31 | $11.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $20.83M derived: sum of 2 quarters · filed 2021-03-03 | $30.46M derived: sum of 3 quarters · filed 2021-08-05 | $40.87M 10-K · filed 2021-03-03 |
| 2020-09-30 | $9.22M 10-Q · filed 2020-10-29 | $18.86M derived: sum of 2 quarters · filed 2021-08-05 | $29.26M 10-Q · filed 2020-10-29 | $41.23M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-06-30 | $9.64M 10-Q · filed 2021-08-05 | $20.04M 10-Q · filed 2021-08-05 | $32.01M derived: sum of 3 quarters · filed 2021-08-05 | $44.82M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $10.40M 10-Q · filed 2021-05-12 | $22.37M derived: sum of 2 quarters · filed 2021-05-12 | $35.18M derived: sum of 3 quarters · filed 2021-05-12 | $47.36M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $11.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $24.78M derived: sum of 2 quarters · filed 2021-03-03 | $36.96M derived: sum of 3 quarters · filed 2021-03-03 | $49.06M 10-K · filed 2021-03-03 |
| 2019-09-30 | $12.81M 10-Q · filed 2020-10-29 | $24.99M derived: sum of 2 quarters · filed 2020-10-29 | $37.09M 10-Q · filed 2020-10-29 | $53.29M derived: sum of 4 quarters · filed 2021-03-03 |
| 2019-06-30 | $12.18M 10-Q · filed 2020-08-04 | $24.28M 10-Q · filed 2020-08-04 | $40.48M derived: sum of 3 quarters · filed 2021-03-03 | $60.05M derived: sum of 4 quarters · filed 2021-03-03 |
| 2019-03-31 | $12.10M 10-Q · filed 2020-05-06 | $28.30M derived: sum of 2 quarters · filed 2021-03-03 | $47.86M derived: sum of 3 quarters · filed 2021-03-03 | $63.07M derived: sum of 4 quarters · filed 2021-03-03 |
| 2018-12-31 | $16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $35.76M derived: sum of 2 quarters · filed 2021-03-03 | $50.97M derived: sum of 3 quarters · filed 2021-03-03 | $63.34M 10-K · filed 2021-03-03 |
| 2018-09-30 | $19.56M 10-Q · filed 2019-11-07 | $34.77M derived: sum of 2 quarters · filed 2019-11-07 | $47.14M 10-Q · filed 2019-11-07 | $57.36M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $15.21M 10-Q · filed 2019-07-31 | $27.57M 10-Q · filed 2019-07-31 | $37.80M derived: sum of 3 quarters · filed 2020-02-28 | $46.28M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $12.36M 10-Q · filed 2019-05-01 | $22.59M derived: sum of 2 quarters · filed 2020-02-28 | $31.07M derived: sum of 3 quarters · filed 2020-02-28 | $41.21M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $18.71M derived: sum of 2 quarters · filed 2020-02-28 | $28.85M derived: sum of 3 quarters · filed 2020-02-28 | $36.29M 10-K · filed 2020-02-28 |
| 2017-09-30 | $8.48M 10-Q · filed 2018-10-31 | $18.63M derived: sum of 2 quarters · filed 2018-10-31 | $26.07M 10-Q · filed 2018-10-31 | $29.68M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $10.14M 10-Q · filed 2018-08-08 | $17.58M 10-Q · filed 2018-08-08 | $21.20M derived: sum of 3 quarters · filed 2019-02-27 | $24.32M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $7.44M 10-Q · filed 2018-05-10 | $11.06M derived: sum of 2 quarters · filed 2019-02-27 | $14.17M derived: sum of 3 quarters · filed 2019-02-27 | $18.19M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $3.62M derived: 10-K 12 month − 6-K 9 month · filed 2019-02-27 | $6.73M derived: sum of 2 quarters · filed 2019-02-27 | $10.75M derived: sum of 3 quarters · filed 2019-02-27 | $14.88M 10-K · filed 2019-02-27 |
| 2016-09-30 | $3.12M 6-K · filed 2017-11-14 | $7.13M derived: sum of 2 quarters · filed 2017-11-14 | $11.26M 6-K · filed 2017-11-14 | |
| 2016-06-30 | $4.01M 6-K · filed 2017-08-07 | $8.14M 6-K · filed 2017-08-07 | ||
| 2016-03-31 | $4.13M 6-K · filed 2017-05-16 | |||
| 2015-12-31 | $22.72M 10-K · filed 2018-03-12 |